---
title: "Stelara (ustekinumab) in plaque psoriasis: Specific populations questions"
description: "Specific populations questions on Stelara (ustekinumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: What side effects did children have on Stelara for psoriasis? How young can children start Stelara for plaque psoriasis? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab) in plaque psoriasis: Specific populations questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)

Specific populations questions that apply to every indication of Stelara are on [Stelara (ustekinumab), all indications: Specific populations](https://www.evicenter.com/medical-information/stelara/specific-populations).

## Pediatric use

<a id="stelara-pediatric-side-effects"></a>

### What side effects did children have on Stelara for psoriasis?

Applies to: Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “The safety of STELARA® was assessed in a study of 44 patients from 6 to 11 years of age (CADMUS Jr) and in a study of 110 patients from 12 to 17 years of age (CADMUS) with moderate to severe plaque psoriasis. The safety profile in these patients through Week 56 or Week 60, respectively, was similar to the safety profile from studies in adults with plaque psoriasis<sup>1,2</sup>
>
> In CADMUS Jr (patients ages 6 to 11), through Week 56, 29 (65.9%) patients reported 1 or more AEs that were considered infections by the investigator. The most common AEs that were considered to be infections were nasopharyngitis (11 [25.0%] subjects), pharyngitis (6 [13.6%] subjects), and upper respiratory tract infection (6 [13.6%] subjects)<sup>1</sup>
>
> In CADMUS (patients ages 12 to 17), through Week 12, the most common AEs were nasopharyngitis (STELARA®, 2.8% [1/36]; placebo, 27.0% [10/37]) and headache (STELARA®, 8.3% [3/36]; placebo, 5.4% [2/37]). Through Week 60, the most common AEs across all treatment arms were nasopharyngitis (34.5% [38/110]), upper respiratory tract infection (12.7% [14/110]), and pharyngitis (8.2% [9/110])<sup>2,3</sup>”

Source: [STELARA: Plaque Psoriasis Treatment for Children ≥12 years| STELARA® (ustekinumab) HCP, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/pediatric-psoriasis/#:~:text=The%20safety%20of%20STELARA%C2%AE%20was,%2812.7%25%20%5B14%2F110%5D%29%2C%20and%20pharyngitis%20%288.2%25)

<a id="stelara-pediatric-age"></a>

### How young can children start Stelara for plaque psoriasis?

Applies to: Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “The safety and effectiveness of STELARA have been established for the treatment 
> of moderate to severe plaque psoriasis in pediatric patients 6 years of age and 
> older who are candidates for phototherapy or systemic therapy.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

> “Use of STELARA in pediatric patients 6 to 11 years of age is supported by evidence from 
> an open-label, single-arm, efficacy, safety, and pharmacokinetics trial (Ps STUDY 4) in 
> 44 subjects [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].
> The safety and effectiveness of STELARA have not been established in pediatric 
> patients less than 6 years of age with plaque psoriasis.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

## Related pages
- [Medical information: Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/storage-and-supply)
